Patents Assigned to ARIAD Pharmaceuticals, Inc.
  • Patent number: 9493470
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 15, 2016
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep Sharma
  • Patent number: 9278971
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 8, 2016
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Patent number: 9273077
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 1, 2016
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Publication number: 20150315194
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep Sharma
  • Publication number: 20150225436
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: April 20, 2015
    Publication date: August 13, 2015
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 9090561
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 28, 2015
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Yihan Wang, Xiaotian Zhu, Rajeswari Sundaramoorthi, Wei-Sheng Huang, Dong Zou, R. Mathew Thomas, Jiwei Qi, Jan Antoinette C. Romero, David C. Dalgarno, William C. Shakespeare, Tomi K. Sawyer, Chester A. Metcalf, III
  • Patent number: 9029533
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Patent number: 9024014
    Abstract: This disclosure concerns a new family of phosphorus-containing compounds of Formula (I): and pharmaceutically acceptable derivatives thereof. Compositions containing such compounds and uses thereof are also provided.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: May 5, 2015
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: David L. Berstein, Leonard W. Rozamus, Yihan Wang, Chester A. Metcalf, III
  • Patent number: 9024028
    Abstract: The invention features methods and compositions for the synthesis of multimerizing agents. An exemplary method for producing AP20187 may comprise: (a) coupling 2-N,Ndimethylaminomethyl-1,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (b) coupling the AP20793 so produced with API7362 to yield AP20187. In particular embodiments, the method further includes the step of producing API7362 by coupling API7360 with methyl-L-pipecolic acid, or a salt thereof.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: May 5, 2015
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Feng Li, Yihan Wang
  • Patent number: 9012462
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: April 21, 2015
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlman, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 8912330
    Abstract: This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: December 16, 2014
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Jiwei Qi, Yihan Wang, Feng Li, William C. Shakespeare, Anna Kohlmann, David C. Dalgarno, Xiaotian Zhu
  • Publication number: 20140349968
    Abstract: The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an ?v62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 27, 2014
    Applicants: ARIAD Pharmaceuticals, Inc., Merck
    Inventors: Jennifer O'Neil, Yair Benita, Shane Marine, Brian Haines
  • Patent number: 8852590
    Abstract: A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 7, 2014
    Assignees: Merck Sharp & Dohme Corp., Ariad Pharmaceuticals, Inc.
    Inventors: Sriram Sathyanarayanan, Christopher Winter, Richard Klinghoffer
  • Patent number: 8846664
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: September 30, 2014
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Wei-Sheng Huang, R. Mathew Thomas
  • Patent number: 8778942
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 15, 2014
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Publication number: 20140171649
    Abstract: The invention features methods and compositions for the synthesis of multimerizing agents. An exemplary method for producing AP20187 may comprise: (a) coupling 2-N,Ndimethylaminomethyl-1,3-diaminopropane with AP20792 to produce the dimeric alcohol, AP20793; and (b) coupling the AP20793 so produced with API7362 to yield AP20187. In particular embodiments, the method further includes the step of producing API7362 by coupling API7360 with methyl-L-pipecolic acid, or a salt thereof.
    Type: Application
    Filed: January 26, 2012
    Publication date: June 19, 2014
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: Feng Li, Yihan Wang
  • Publication number: 20140066434
    Abstract: The invention discloses methods and compositions for treating or preventing Parkinson's disease by administering a compound of Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.
    Type: Application
    Filed: April 6, 2012
    Publication date: March 6, 2014
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventor: William C. Shakespeare
  • Publication number: 20140066406
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 6, 2014
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventor: ARIAD PHARMACEUTICALS, INC.
  • Publication number: 20140045826
    Abstract: The invention discloses methods and compositions for treating or preventing neurodegenerative disease by administering a compound of Formula I: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.
    Type: Application
    Filed: April 6, 2012
    Publication date: February 13, 2014
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: William C. Shakespeare, Frank G. Haluska
  • Publication number: 20140024620
    Abstract: The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.
    Type: Application
    Filed: October 14, 2011
    Publication date: January 23, 2014
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu, Victor M. Rivera, Juan J. Miret